- Recursion Pharmaceuticals (Nasdaq: RXRX) is a clinical-stage TechBio company focused on decoding biology to improve lives through AI-driven drug discovery, recently achieving a pivotal transition from theoretical to clinical validation.
- In 2025, Recursion reported a revenue growth of 27% to $74.7 million, driven by strategic partnerships, including a significant milestone payment of $134 million from Sanofi, and achieved its first AI-enabled clinical proof of concept in familial adenomatous polyposis (FAP).
- The company has established collaborations with major pharmaceutical players such as Sanofi, Roche, and Genentech, securing over $500 million in cumulative payments, which underscores its growing influence in the biotech sector.
- Ideal buyers for Recursion's solutions include pharmaceutical companies seeking innovative drug discovery methods to address complex diseases, as Recursion's AI platform offers a unique capability to translate biological insights into meaningful patient outcomes.
Engineering is Recursion’s largest group with roughly 306 employees, accounting for close to half of total headcount and reflecting the company’s emphasis on data science and software-driven research. Business Management (83 employees) and Information Technology (79 employees) follow, highlighting the operational and infrastructure support required for large-scale experimental platforms. Finance & Administration (44), Marketing & Product (41), and Operations (37) provide additional backbone functions, while Healthcare specialists (24) focus on clinical and scientific rigor. Smaller teams in Human Resources (15) and Sales & Support (15) manage people programs and external partnerships, and an "Other" category of 22 covers niche or interdisciplinary roles. The overall mix shows a technology-heavy workforce balanced by essential business and scientific functions.
Headquarters operations in Salt Lake City, Utah, employ about 211 people, making it the single largest named office. A significant remote or flexible workforce is captured in the "Other" category with 294 employees, illustrating Recursion’s distributed hiring approach. Outside the United States, Oxford in the United Kingdom hosts 51 employees, while Toronto houses 41, signaling a growing North American and European footprint. Additional clusters can be found in San Francisco (26), London (13), Boston (11), Montreal (7), San Jose (6), and New York (6), suggesting strategic placement near academic, biotech, and technology hubs to access specialized talent and partnerships.
